{"filing":{"accession_number":"0001104659-26-076044","cik":"0001590560","ticker":"QURE","company_name":"uniQure N.V.","form":"8-K","filing_date":"2026-06-22","report_date":null,"primary_document":"qure-20260619x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1590560/000110465926076044/qure-20260619x8k.htm"},"events":[{"id":12551,"run_id":11129,"accession_number":"0001104659-26-076044","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"uniQure announced preliminary Phase I/IIa clinical trial data for AMT-260 in refractory mesial temporal lobe epilepsy, showing that 3 of 6 patients achieved meaningful seizure reductions (79-100% decline) with no serious adverse events and favorable tolerability. This represents a material clinical development milestone for the company's gene therapy pipeline.","company_name":"uniQure N.V.","ticker":"QURE","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9426,"accession_number":"0001104659-26-076044","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"uniQure disclosed preliminary clinical trial data for AMT-260 in a Phase I/IIa trial for refractory mesial temporal lobe epilepsy, showing early biological signals of therapeutic activity with favorable tolerability (no serious adverse events, mild-to-moderate adverse events only). This is a material operational/clinical milestone for a gene therapy company, but does not fit the specific event types of earnings release, exec changes, M\u0026A, impairment, litigation, or other named categories. The disclosure is furnished under Item 7.01 (Regulation FD Disclosure) and represents a significant clinical development that would affect investor assessment of the company's pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T10:51:10.711790+00:00","company_name":"","ticker":null,"filing_date":""},{"id":9427,"accession_number":"0001104659-26-076044","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"uniQure announced preliminary Phase I/IIa clinical trial data for AMT-260 in refractory mesial temporal lobe epilepsy, showing that 3 of 6 patients achieved meaningful seizure reductions (79-100% decline) with no serious adverse events and favorable tolerability. This is a material clinical development milestone for a gene therapy candidate in active development, but does not fit the specific event types (earnings, M\u0026A, impairment, litigation, etc.); it is a clinical/operational milestone disclosure appropriately classified as operational_other.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T10:51:10.711790+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9426,"accession_number":"0001104659-26-076044","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"uniQure disclosed preliminary clinical trial data for AMT-260 in a Phase I/IIa trial for refractory mesial temporal lobe epilepsy, showing early biological signals of therapeutic activity with favorable tolerability (no serious adverse events, mild-to-moderate adverse events only). This is a material operational/clinical milestone for a gene therapy company, but does not fit the specific event types of earnings release, exec changes, M\u0026A, impairment, litigation, or other named categories. The disclosure is furnished under Item 7.01 (Regulation FD Disclosure) and represents a significant clinical development that would affect investor assessment of the company's pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T10:51:10.711790+00:00","company_name":"uniQure N.V.","ticker":"QURE","filing_date":"2026-06-22"},{"id":9427,"accession_number":"0001104659-26-076044","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"uniQure announced preliminary Phase I/IIa clinical trial data for AMT-260 in refractory mesial temporal lobe epilepsy, showing that 3 of 6 patients achieved meaningful seizure reductions (79-100% decline) with no serious adverse events and favorable tolerability. This is a material clinical development milestone for a gene therapy candidate in active development, but does not fit the specific event types (earnings, M\u0026A, impairment, litigation, etc.); it is a clinical/operational milestone disclosure appropriately classified as operational_other.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T10:51:10.711790+00:00","company_name":"uniQure N.V.","ticker":"QURE","filing_date":"2026-06-22"}]}